Professor Michal Novak enters a new position in AXON Neuroscience, the new CSO was named Assoc. Prof. Norbert Zilka
Biotech company AXON Neuroscience, which is currently a driving force in the development of disease modifying treatments for Alzheimer’s disease(AD), is pleased to announce that Prof. Michal Novak, has been appointed as a Chairman of the Scientific Advisory Board of AXON Neuroscience , effective from October 1, 2015. Assoc. Prof. Norbert Zilka, previously AXON’s Head of Preclinical Trials, was named the company’s new Chief Science Officer.
„Prof. Novak is the author of ground-breaking discoveries, which were essential for new approaches in the development of the disease modifying treatment of AD. His vision sets the course not only for our company, but based on the recent development of AD therapeutic approaches, for the whole industry. We are delighted that he will continue to support AXON Neuroscience from his new position, which will leave him more space to focus on developing new products and making AXON‘s portfolio stronger and more diversified,“ said Roman Sivak, AXON’s CEO, after the Board meeting.
Professor Michal Novak co-discovered the main component of neurofibrillary degeneration, a key element of Alzheimer’s disease. He spent 10 years working at the Laboratory of molecular Biology, MRC in Cambridge in a team with three Nobel laureates Sir Aaron Klug, Cesar Milstein and John Walker. In 1999 he co-founded a biotech company AXON Neuroscience. Prof. Novak also founded the Institute of Neuroimmunology of the Slovak Academy of Sciences (SAV), the Memory foundation, the Slovak Alzheimer’s Association, and the Slovak Society for Neuroscience. In addition, he is a co-founder of the largest global research initiative aimed at tackling the challenges of neurodegenerative diseases – Joint Programming on Neurodegenerative Disorders.
As the Head of Preclinical Trials, Assoc. Prof. Norbert Zilka was previously responsible for creating novel animal models for human neurodegenerative disorders and preclinical development of immunotherapeutics. He is the author of the tau immunological cascade in Alzheimer’s disease. Assoc. Prof. Zilka was a national coordinator of Biomarkers for Alzheimer’s disease and Parkinson’s disease, a project running under the Joint Programming Neurodegenerative Disease grant scheme. He is also a co-author of the project Synaptic Dysfunction in Alzheimer’s Disease funded by Marie Sklodowska-Curie Innovative Training Network and was a national coordinator and chairman of the Neuroscience session at the first Frontiers of Science Meeting organized by the Royal Society and V4 countries in 2010. Norbert Zilka has been working with Prof. Novak since the foundation of the company in 1999 and played the key role in the leading discoveries, which he further helped to transform into AXON‘s portfolio of products.
+421 902 161 362
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00 | Pressemelding
Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom